1 / 15

Next generation sequencing for breast cancer

Next generation sequencing for breast cancer. Helen Lindsay Leeds DNA lab. Sanger sequencing. Targeted approach with each reaction representing a single PCR product (up to ~1kb) Analysis trace represents an average result from thousands of molecules Capacity up to ~1Mb/day.

ghita
Download Presentation

Next generation sequencing for breast cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Next generation sequencing for breast cancer Helen Lindsay Leeds DNA lab

  2. Sanger sequencing • Targeted approach with each reaction representing a single PCR product (up to ~1kb) • Analysis trace represents an average result from thousands of molecules • Capacity up to ~1Mb/day

  3. BRCA screening: previous method • 15 patient panels set up every 10d • 40d turnaround time • For each panel: • Sanger sequencing of BRCA1 and BRCA2 • 10 x 96 well plates covering 59 amplicons • Tecan robots, M13 tagged primers, barcoding • protein truncation test – BRCA2 exon 11 (3x) • MLPA (2x) • any sequencing repeats and confirmations required • 1 lead scientist plus 3 technicians to cover workload

  4. Second generation sequencing • Entire input sample is sequenced • Millions of small DNA fragments sequenced in parallel • Each sequence read represents a single starting DNA molecule • Capacity up to ~25Gb per day (~25,000x Sanger approach)

  5. Clonal sequencing of BRCA • 20 patient panels set up every 10d • 40d turnaround time • For each panel: • clonal sequencing of BRCA1 and BRCA2 on Illumina GAIIx • MLPA (2x) • any confirmations/repeats required (Sanger sequencing) • 1 lead scientist plus 2 technicians to cover workload • Increase throughput, lower costs

  6. Library preparation I • Target enrichment of BRCA1 and BRCA2: • long PCR of the complete CDS of BRCA1 and BRCA2 in 22 amplicons (1.2-5.8kb) • Shearing of pooled PCR products using the Covaris S2 instrument and verification using the Agilent Bioanalyzer

  7. Library preparation II • End repair, A addition and ligation of tagged (6bp barcode) adaptors • Agarose gel size selection and gel extraction • Enrichment PCR and verification on the Agilent Bioanalyzer • Quantification and pooling of tagged samples

  8. Cluster generation • Hybridise to flow cell • Bridge amplification • Cleave reverse strands • Hybridise sequencing primer

  9. Sequencing • Copy template using fluorescently labelled, reversibly terminated nucleotides • Capture fluorescence signal after each incorporation step • Remove blocking group to allow addition of next base

  10. Data analysis • Data analysis using NextGENe (SoftGenetics) software • conversion to appropriate format • remove low quality files • tag sorting • alignment to reference sequence • Generation of mutation reports • manual inspection to confirm variants and exclude artefacts • Generation of coverage information; custom spreadsheets automatically check coverage at each base over the region of interest • a minimum threshold of 50-fold coverage is required for diagnostic screening

  11. mutation report alignment coverage

  12. Post analysis • Confirmation of all sequence variants other than known neutral polymorphisms by Sanger sequencing • Sanger sequencing of any regions with less than 50-fold coverage • Creation of a diagnostic report combining sequence data with MLPA results

  13. Discussion • To date we have sequenced and reported ~300 patients, with a 10% pick-up rate of pathogenic mutations (excluding dosage abnormalities) • All mutations and UVs confirmed by Sanger sequencing • 100% concordance • 40% reduction in average test cost • 50% reduction in hand-on staff time • most significant reduction in sequence checking time • 30-40% reduction in consumables costs • Improvement in turnaround times

  14. Future developments • Alternative enrichment techniques • high throughput long PCR • hybridisation based target capture • Automation of library preparation • Optimise protocol to detect dosage changes • More diseases • HNPCC in final stages of validation • potential for testing more genes in parallel

  15. Acknowledgements • Leeds DNA lab • Nick Camm • Rachel Robinson • Ruth Charlton • Leeds Institute of Molecular Medicine • Heather Fraser • Jo Morgan • Graham Taylor

More Related